Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
NUVB filed a Form 144 notice indicating a planned sale of 100,000 common shares. The filing lists an aggregate market value of $485,000 and identifies Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) as the broker. The approximate date of sale is 10/27/2025, and the shares are listed on the NYSE.
The seller acquired the shares on 10/27/2025 through an exercise of stock options from the issuer, with cash as the form of payment. The filing also notes 342,272,722 shares outstanding.
Robert Mashal, a director of Nuvation Bio Inc. (NUVB), reported derivative security transactions dated 08/11/2025 involving stock options with a $1.55 exercise/conversion price. The filing lists two entries of 350,001 option instruments each, with an exercisable/expiration date shown as 01/07/2034.
The filing states the shares underlying the options are fully vested and explains the reported transaction involved transfer of an option to the reporting person’s irrevocable trust. Post-transaction beneficial ownership shown on the form is 391,178 derivative securities held directly and 350,001 held indirectly (by trust).
Nuvation Bio (NUVB) Q2 2025 10-Q snapshot
- Total revenue rose to $4.83 million (vs. $1.44 million Q2 2024) driven by the first U.S. sales of IBTROZI ($1.24 million) and higher collaboration income.
- Gross profit reached $2.26 million; operating loss narrowed to $63.6 million from $470.4 million (prior period included $425 million IPR&D charge).
- Net loss was $59.0 million, or $0.17 per share, versus $462.5 million, or $1.89, a year ago. Six-month loss totals $112.2 million.
- Liquidity remains strong: cash and cash equivalents $247.9 million, marketable securities $359.8 million—about $607.7 million available, which management believes funds operations for ≥12 months.
- Balance-sheet leverage increased: $150 million revenue-interest financing and $47 million term loan lifted total liabilities to $274.3 million (up from $76.8 million at 12/31/24).
- R&D expense $27.4 million; SG&A $38.5 million support commercialization and pipeline. Shares outstanding: 342.3 million (7/31/25).
While the launch of IBTROZI establishes an initial revenue base, sustained losses, higher debt and continued heavy R&D spend underscore the need for successful market penetration and additional approvals to reach profitability.
Insider Trading Alert: Stacy Markel, Chief People Officer of Nuvation Bio (NUVB), purchased 10,000 shares of Class A Common Stock on June 18, 2025, at a price of $1.71 per share, representing a total investment of $17,100.
Following this transaction, Markel now holds 29,591 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed as a direct ownership transaction.
This insider buying activity by a key executive officer could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with SEC regulations, with the filing submitted through an attorney-in-fact, Stephen Dang.
Nuvation Bio CFO Philippe Sauvage reported two insider purchase transactions of Class A Common Stock:
- On June 16, 2025: Acquired 3,300 shares at $1.835 per share
- On June 17, 2025: Acquired 4,000 shares at $1.79 per share
Following these transactions, Sauvage's direct ownership increased to 9,902 shares. The filing notes that his holdings include 2,602 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. These insider purchases by the CFO, totaling 7,300 shares over two consecutive days, may signal management's confidence in the company's valuation and future prospects.
Insider Purchase Alert: Colleen Sjogren, Chief Commercial Officer of Nuvation Bio (NUVB), has acquired 50,000 shares of Class A Common Stock on June 16, 2025, at a weighted average price of $1.807 per share, representing a total investment of approximately $90,350.
Following this transaction, Sjogren now beneficially owns 81,000 shares directly, which includes 3,000 shares previously acquired through the company's 2021 Employee Stock Purchase Plan on May 19, 2025. The purchase was executed in multiple transactions with prices ranging from $1.795 to $1.82 per share.
This insider purchase by a senior executive could signal confidence in the company's future prospects. The transaction was reported via Form 4 filing and executed in compliance with securities regulations, with the filing submitted through an attorney-in-fact on June 18, 2025.
Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio (NUVB), reported significant insider purchases on June 16, 2025. The transactions involved:
- First purchase: 26,000 shares of Class A Common Stock at $1.79 per share
- Second purchase: 24,000 shares of Class A Common Stock at $1.80 per share
Following these transactions, Wentworth directly owns a total of 50,000 shares of Class A Common Stock. The insider's substantial purchase of shares, totaling approximately $89,740, could signal confidence in the company's future prospects. The Form 4 was filed through an attorney-in-fact, Stephen Dang, on June 18, 2025.
David Hung, President, CEO, Director, and 10% owner of Nuvation Bio (NUVB), has made a significant insider purchase of 500,000 shares of Class A Common Stock on June 16, 2025. The shares were acquired at a weighted-average price of $1.787 per share, with purchase prices ranging from $1.64 to $1.88.
Following this transaction, Hung's direct ownership increased to 59,281,054 shares. The substantial purchase by the company's chief executive, representing an investment of approximately $893,500, may signal management's confidence in the company's future prospects.
Key transaction details:
- Transaction type: Direct purchase of common stock
- Total transaction value: ~$893,500
- Filing was signed by Stephen Dang as attorney-in-fact
- No derivative securities were involved in this transaction